1. Home
  2. YSG vs ARMP Comparison

YSG vs ARMP Comparison

Compare YSG & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$2.16

Market Cap

267.5M

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$8.14

Market Cap

295.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
ARMP
Founded
2016
N/A
Country
China
United States
Employees
N/A
61
Industry
Package Goods/Cosmetics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.5M
295.5M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
YSG
ARMP
Price
$2.16
$8.14
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
104.3K
76.9K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.08
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$1.74
52 Week High
$11.04
$14.98

Technical Indicators

Market Signals
Indicator
YSG
ARMP
Relative Strength Index (RSI) 21.63 40.74
Support Level N/A $7.43
Resistance Level $3.10 $12.11
Average True Range (ATR) 0.18 1.23
MACD -0.05 -0.14
Stochastic Oscillator 0.53 28.86

Price Performance

Historical Comparison
YSG
ARMP

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: